

Hướng dẫn sử dụng bản gốc

Tài liệu được cung cấp bằng tiếng Anh

Tài liệu được xác nhận bằng chữ ký số

Tp Hà Nội ngày 15 tháng 04 năm 2022

REF C88012A



2 × 50 Tests



INTENDED USE

The iFlash-EB NA IgA assay is a paramagnetic particle chemiluminescent immunoassay (CLIA) for the qualitative determination of IgA antibody to Epstein-Barr virus nuclear antigen (EB NA) in human serum and plasma using the iFlash Immunoassay Analyzer.

SUMMARY AND EXPLANATION

Epstein-Barr virus (EBV) is a member of the herpesvirus family and a worldwide infectious agent that is the classic cause of infectious mononucleosis (IM). IM is often diagnosed based on the presence of characteristic symptoms of sore throat, lymphadenopathy and fever, along with a positive heterophile antibody test and a characteristic hematological picture of lymphocytosis (> 50%) with 10% or more of the lymphocytes identified as atypical.

Clinical manifestations similar to infectious mononucleosis can also be induced by a number of other pathogenic infectious agents including cytomegalovirus, Toxoplasma gondii, hepatitis viruses, human immunodeficiency virus (HIV), and others. The term mononucleosis syndrome is often applied until the specific etiologic agent is identified. Confirmation of an acute diagnosis of EBV infectious mononucleosis is generally sought by a positive heterophile antibody test (agglutination by patient's serum with horse or sheep red blood cells). However, difficulties in diagnosis arise when the heterophile test is negative or when clinical manifestations are atypical.

ASSAY PRINCIPLE

The iFlash-EB NA IgA assay is an indirect immunoassay.

- 1st incubation: Anti-EB NA IgA in the sample and EB NA antigen-coated paramagnetic microparticles react to form a complex.
- Wash: The unbound materials are washed away from the solid phase in a magnetic field.
- 2nd incubation: Acridinium-ester-labeled anti-human IgA conjugate is added to form a reaction mixture.
- Another wash.
- Trigger of signal: The Pre-Trigger and Trigger Solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs).
- A direct relationship exists between the amount of anti-EB NA IgA in the sample and the RLUs detected by the iFlash optical system.
- Results are determined by comparing the RLUs of each sample to the cutoff signal obtained from a previous calibration.

REAGENTS

Reagent kit, 100 tests, 2 packs, 50 tests /pack

R1	EB NA antigen-coated paramagnetic microparticles, 3.5 mL/pack, 0.05% ProClin 300.
R2	Acridinium-ester-labeled anti-human IgA conjugate, 6.5 mL/pack; 0.05% ProClin 300.
R3	Sample diluent, phosphate buffer, 6.5 mL/pack; 0.05% ProClin 300.
CAL1	Calibrator 1, 1 bottle, 1.0 mL, Tris buffer, protein stabilizers, 0.05% ProClin 300.
CAL2	Calibrator 2, 1 bottle, 1.0 mL, anti-EB NA IgA in

Tris buffer with protein stabilizers, 0.05% ProClin 300.

MATERIALS REQUIRED (BUT NOT PROVIDED)

- REF C89999/C89959/C89949, iFlash Pre-Trigger Solution: hydrogen peroxide solution.
- REF C89998/ C89958/ C89948, iFlash Trigger Solution: sodium hydroxide solution.
- REF C89997, iFlash Wash Buffer: phosphate buffered saline solution with 0.05% ProClin 300.
- REF C80001, iFlash Wash Buffer (10×): phosphate buffered saline solution with 0.05% ProClin 300.
- REF C89996, reaction vessels.

WARNINGS AND PRECAUTIONS

IVD For in vitro diagnostic use

- The calibrators (CAL1 and CAL2) have been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg, anti-HCV, and anti-HIV-1/2 by approved methods.
- However, as no known test method can offer the complete assurance that products derived from human sources will not transmit infection. Therefore, all humanized materials should be considered potentially infectious.
- Exercise the normal precautions required for handling all laboratory reagents.
- Disposal of all waste material should be in accordance with local guidelines.
- Wear gloves when handling specimens or reagents.
- Clean and disinfect all spills of specimens or reagents using a suitable disinfectant.
- iFlash Trigger solution contains sodium hydroxide (NaOH) and should be avoided contact with eyes.
- For further information on warnings and precautions, see Annex B.

REAGENT HANDLING

- The reagents may not be used after the stated expiration date.
- Avoid the formation of foam with all reagents.
- The reagents in the pack and calibrators are ready for use.
- Close the bottles of calibrator right after calibration and store at 2-8°C.
- Do not pool reagents within a reagent kit or between reagent kits.
- Prior to loading the iFlash-EB NA IgA reagent pack on the system for the first time, resuspend the microparticles by inverting the reagent pack slightly.
- For further information on reagent handling precautions during system operation, refer to the iFlash system operating instruction.

STORAGE AND STABILITY

Storage:

- Store at 2-8°C in an upright position.
- The kit may be used immediately after removal from 2-8°C storage.

Stability:

- Unopened at 2-8°C: up to the stated expiration date.
- Opened at 2-8°C: 28 days.
- Store on-board: 28 days.

SPECIMEN COLLECTION AND PREPARATION

- Serum or plasma (lithium heparin, sodium heparin potassium EDTA, and sodium citrate) are the recommended samples. Other anticoagulants have not been validated for use with the iFlash-EB NA IgA assay.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation.
- Centrifuge the specimens.
- Store specimens at room temperature (20 to 25°C) for no longer than 8 hours.
- If the testing will not be completed within 8 hours, refrigerate the samples at 2 to 8°C.
- If the testing will not be completed within 14 days, or for shipment of samples, freeze at -20°C or colder.
- Frozen specimens must be mixed thoroughly after thawing.
- The samples may be frozen for maximum 3 times.
- Centrifuge specimens with a lipid layer on the top, and transfer only the clarified specimen without the lipemic material.
- Ensure that residual fibrin and cellular matter have been removed prior to analysis.
- Use with caution in handling patient specimens to prevent cross-contamination.
- Do not use heat-inactivated samples.
- Ensure the patient samples, calibrators and controls are at ambient temperature (20-25°C) before measurement.
- Due to the possible evaporation, specimens and calibrators on the analyzers should be measured within 2 hours.

ASSAY PROCEDURE

- Refer to the system operating instruction or the online help system for detailed information on preparing the system.
- The test-specific parameters stored in barcode on the reagent pack are read in. In case the barcode cannot be read, enter the sequence numbers.
- Carry out calibration, if necessary.
- Place the calibrators CAL1 and CAL2 in the calibrator rack in the sample zone. Only keep calibrators open during calibration.
- Test application.
- Load samples (20 µL of sample is needed for each determination in addition to the sample container and system dead volumes).
- Click RUN, the iFlash System performs all the functions automatically and calculates the results.

CALIBRATION

- Every iFlash-EB NA IgA reagent kit has a QR code label containing the specific information for calibration of the particular reagent lot.
- To perform an iFlash-EB NA IgA calibration, test CAL1 and CAL2 in duplicate and the software calculate the cutoff value based on the RLUs of the two calibrators and information from the QR code.
- Once an iFlash-EB NA IgA calibration is accepted and stored, all subsequent samples may be tested without further calibration unless:
 - After 28 days when using the same reagent lot.
 - A reagent kit with a new lot number is used.
 - Controls are out of range.

- Required by pertinent regulations.

QUALITY CONTROL

Quality control materials should be run as single determinations at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. Include commercially available quality control materials that cover at least two levels of analyte. Follow manufacturer's instructions for reconstitution and storage. Each laboratory should establish mean values and acceptable ranges to assure proper performance. Quality control results that do not fall within acceptable ranges may indicate invalid test results.

RESULT**Calculation:**

The iFlash system automatically calculates the analyte concentration of each sample. The results are given in COI.

Interpretation of Results

- Nonreactive: $COI < 0.9$
- Indeterminate: $0.9 \leq COI < 1.1$
- Reactive: $COI \geq 1.1$

Individuals with nonreactive results indicate the absence of acute infection.

Samples with indeterminate result should be retested. In case the result is still indeterminate, a second sample should be collected within an appropriate period of time (e.g. 2 weeks).

A reactive result indicates acute infection. Such individuals are potentially at risk of transmitting EB infection.

LIMITATIONS

- The iFlash-EB NA IgA assay is limited to the determination of EB NA IgA in human serum or plasma (lithium heparin, sodium heparin, potassium EDTA, and sodium citrate). It has not been validated for use with other types of plasma.
- The use of serum separator (gel) blood collection tubes has been validated for use with this assay. However, it is not possible to survey all manufacturers or tube types.
- If the results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
- For diagnostic purposes, the results should be interpreted in light of the total clinical presentation of the patient, including symptoms, clinical history results.
- Specimens from heparinized patients may be partially coagulated and erroneous results could occur due to the presence of fibrin.
- The results from an alternative assays (i.e. EIA or RIA) may not be equivalent and cannot be used interchangeably.
- The assay is unaffected by icterus (bilirubin < 30 mg/dL), hemolysis (Hb < 1,500 mg/dL), lipemia (Intralipid < 1,500 mg/dL) and total serum protein (< 10 g/dL).
- No interference was observed from rheumatoid factors up to a concentration of 2,000 IU/mL.
- No interference was observed from anti-nuclear antibodies up to a concentration of 500 U/mL.
- No interference was observed from HAMA up to a concentration of 600 ng/mL.

PERFORMANCE CHARACTERISTICS

Below are the representative performance data, and the results obtained in individual laboratories may differ

Precision

The iFlash-EB NA IgA is designed to have a precision of $\leq 10\%$ total CV.

The precision of iFlash-EB NA IgA was determined using EB NA IgA reagents, samples and controls. Two serum samples, consisting low and high concentration of anti-EB NA IgA were assayed.

The within run precision was determined by testing each sample in replicates of 10 ($n = 10$), and calculating percent coefficient of variation (%CV). The results of the study are shown below:

Sample	Mean (COI)	SD	%CV
1	1.22	0.02	1.64
2	10.87	0.20	1.84

The between run precision was determined by testing each sample in duplicate, two separate runs daily for 20 days ($n = 80$), and calculating percent coefficient of variation (%CV). The results of the study are shown below:

Sample	Mean (COI)	SD	%CV
1	2.50	0.23	9.20
2	12.88	1.20	9.32

Analytical Specificity

The analytical specificity of iFlash-EB NA IgA assay was evaluated with viral antibody specimens. The nonreactive EB NA IgA status of each specimen was verified using a commercially available EB NA IgA assay.

Clinical Category	Number of Specimens	iFlash-EB NA IgA Nonreactive
Toxo IgM	5	5
CMV IgM	6	6
HSV 1+2 IgM	5	5
Rubella IgM	6	6
<i>C. Pneumonia</i> IgM	5	5
TP IgM	7	7
EB VCA IgM	6	6
EB NA IgG	5	5
EB VCA IgG	5	5
EB VCA IgA	5	5
EB EA IgM	5	5
Toxo IgG	5	5
Rubella IgG	5	5
CMV IgG	5	5
HSV 1+2 IgG	5	5
Anti-HAV IgM	5	5
Anti-HBc IgM	5	5
HIV Combo	5	5
<i>C. Pneumonia</i> IgG	5	5
<i>M. Pneumonia</i> IgM	5	5
<i>M. Pneumonia</i> IgG	5	5

ADV	5	5
FLUA	5	5
FLUB	5	5
PIVs	5	5
Total Samples	130	130

Relative Sensitivity

Relative sensitivity of iFlash-EB NA IgA assay was determined by testing samples that were found reactive in a commercially available EB NA IgA assay. A total of 205 samples including sequential and single samples were tested with iFlash-EB NA IgA assay.

Clinical Category	Number of Specimens	Number of Reactive Specimens	Relative Sensitivity
EB infected	205	196	95.61%

Relative Specificity

Relative specificity of iFlash-EB NA IgA assay was determined by testing samples that were found nonreactive in a commercially available EB NA IgA assay. A total of 592 samples were tested with iFlash EB NA IgA assay.

Clinical Category	Number of Specimens tested	Number of Non-reactive Specimens	Relative Specificity
Hospitalized patients	592	589	99.49%

REFERENCES

- Desgranges C, Bornkamm GW, Zeng Y, et al. Detection of Epstein-Barr viral DNA internal repeats in the nasopharyngeal mucosa of Chinese with IgA/EBV-specific antibodies. *Int J Cancer*. 1982 Jan 15; 29(1): 87-91.
- Takimoto T, Furukawa M, Morishita K, et al. Nasopharyngeal carcinoma in Japan--clinical evaluation of EBV serology and EBV-associated nuclear antigens test. *Auris Nasus Larynx*. 1982; 9(3): 151-63.
- Hayashi Y, Matsumura Y, Nishihira T, et al. Burkitt's lymphoma cell line bearing surface IgA and negative for nuclear antigen of Epstein-Barr virus (EBNA). *Jpn J Exp Med*. 1980 Dec; 50(6): 423-34.
- Czeplédy J, Gergely L, Váczi L, et al. Demonstration of EBNA (Epstein-Barr virus nuclear antigen) antibodies of different immunoglobulin classes. *Acta Microbiol Acad Sci Hung*. 1978; 25(4): 237-43.
- Foong YT, Cheng HM, Sam CK, Dillner J, et al. Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. *Int J Cancer*. 1990 Jun 15; 45(6): 1061-4.
- Shimakage M, Ikegami N, Chatani M, et al. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma(NPC) after radiation therapy. *Biken J*. 1987 Jun; 30(2): 45-51.
- Chow KC, Ma J, Lin LS, et al. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. *Cancer Epidemiol Biomarkers Prev*. 1997 May; 6(5): 363-8.
- Chen MR, Yang JF, Hsu TY, et al. Use of bacterially expressed GST/EBNA-1 fusion proteins for detection

of antibodies in sera from patients with nasopharyngeal carcinoma and healthy donors. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1996 May; 29(2): 65-79.

- Mathew A, Cheng HM, Sam CK, et al. Serum IgA cross-reactivity between glycine-alanine repeat sequence of EBNA-1 and keratin or collagen in nasopharyngeal carcinoma. Clin Immunol Immunopathol. 1994 May; 71(2): 164-8.

SHENZHEN YHLO BIOTECH CO., LTD.



Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, PEOPLE'S REPUBLIC OF CHINA

Wellkang Ltd (www.CE-marking.eu)



Suite B, 29 Harley St., London W1G 9QR, UK

ANNEX A:

Explanation of abbreviation

Abbreviation	Explanation
	Product No.
	Calibrator
	Reagent
	Number of tests
	Manufactured by
	EU Representative
	EC Declaration of Conformity
	Caution
	Instructions for use
	In vitro diagnostic medical device
	Lot No.
	Date of manufacture
	Expiry date
	Biohazard Symbol

GHS07 	Pictograms for Caution
GHS09 	Pictograms for Hazardous to the aquatic environment

ANNEX B:

WARNINGS AND PRECAUTIONS (Proclin 300)

- Hazardous Component: 0.05% Proclin 300
(Reaction mass of: 5-chloro-2-methyl-4-isothiazolin [EC no. 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC no. 200-239-6] (3:1))
- Hazard Statement:
H317: May cause an allergic skin reaction.
H319: Causes serious eye irritation.
H410: Very toxic to aquatic life with long-lasting effects.
- Precautionary Statement:
P261: Avoid breathing dust/fume/gas/mist/vapours/spray.
P264: Wash hands thoroughly after handling.
P272: Contaminated work clothing should not be allowed out of the workplace.
P280: Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337+P313: If eye irritation persists: Get medical advice/attention.
P333+P313: If skin irritation or rash occurs: Get medical advice/attention.
P302+P352: IF ON SKIN: Wash with plenty of soap and water.
P321: Seek immediate care from a doctor.
P363: Wash contaminated clothing before reuse.
P273: Avoid release to the environment.
P391: Collect spillage.
P501: Dispose of contents/container in a safe way.